Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Deltarasin + Infigratinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Deltarasin | KRAS Inhibitor 18 | Deltarasin is an inhibitor of the interaction between Kras and the prenyl-binding protein PDEdelta, resulting in decreased KRAS signaling, and potentially leading to reduced tumor cell proliferation and inhibition of tumor growth (PMID: 23698361). | ||
Infigratinib | Truseltiq | BGJ398|BGJ-398|BGJ 398 | FGFR Inhibitor (Pan) 26 | Truseltiq (infigratinib) is a pan-FGFR inhibitor, which inhibits tumor angiogenesis and tumor cell proliferation (PMID: 31109923, PMID: 30101387). Truseltiq (infigratinib) is FDA approved for use in patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusion or rearrangement (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|